Active — Not RecruitingNot Applicable

Metastatic Tumor Research and Outcomes Network

United States, Australia, Canada960 participantsStarted 2017-11-15

Plain-language summary

The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient 18 or older. * Patient diagnosed with a metastatic tumor of the spine * Informed consent obtained, i.e.: * Ability to understand the content of the patient information/ICF * Willingness and ability to participate in the registry according to the Registry Plan * Signed and dated EC/IRB approved written informed consent (if consent is required by the EC/ IRB at the registry site) Exclusion Criteria: • Patient diagnosed with a primary tumor of the spine.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Patient details

Timeframe: collected at baseline

Tumor details

Timeframe: collected at baseline, first prospective treatment and follow-up

Symptoms

Timeframe: collected at baseline, first prospective treatment and follow-up

Treatment details - previous treatment of the index of the spine

Timeframe: Collected at baseline

Imaging information

Timeframe: collected at baseline, first prospective treatment, discharge and at follow-up.

Patient reported outcomes - Euroqol EQ-5D-3L / - EQ-5D VAS

Timeframe: collected at baseline, first prospective treatment, discharge and at follow-up.

Ambulation

Timeframe: collected at baseline, discharge and at follow-up.

Trial details

NCT IDNCT02830451

SponsorAO Innovation Translation Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08-15

View on ClinicalTrials.gov More Metastatic Spine Tumor trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Patient details

Timeframe: collected at baseline

Tumor details

Timeframe: collected at baseline, first prospective treatment and follow-up

Symptoms

Timeframe: collected at baseline, first prospective treatment and follow-up

Treatment details - previous treatment of the index of the spine

Timeframe: Collected at baseline

Imaging information

Timeframe: collected at baseline, first prospective treatment, discharge and at follow-up.

Patient reported outcomes - Euroqol EQ-5D-3L / - EQ-5D VAS

Timeframe: collected at baseline, first prospective treatment, discharge and at follow-up.

Ambulation

Timeframe: collected at baseline, discharge and at follow-up.